Pharmacokinetic and pharmacodynamic modeling of oral mitiglinide on glucose lowering in healthy Chinese volunteers

Shijia Liu1, Peidong Chen2, Yang Zhao3, Guoliang Dai1, Bingting Sun2, Yao Wang1, Anwei Ding2 and Wenzheng Ju1*

Abstract

Background: Mitiglinide is a widely used agent for diabetic treatment. We established a pharmacokinetic-pharmacodynamic (PK-PD) model to illustrate the relationship between mitiglinide plasma concentration and its glucose lowering effects in healthy volunteers.

Methods: The volunteers participated in the test after the administration of a single dose of 10 mg mitiglinide. The drug concentration in plasma and the values of glucose levels were determined by LC-MS/MS assay and hexokinase method. A PK-PD model was established with a series of equations to describe the relationship between plasma medicine and glucose, and the equations were solved numerically and fitted to the data with the Phoenix NLME software.

Results: The results of the two-compartment model analysis were based on the maximum likelihood criterion and visual inspection of the fittings. The terminal elimination half-life (t1/2) was 1.69 ± 0.16 h and the CL/F was 7.80 ± 1.84 L/h. The plasma glucose levels began to decline by 0.2 h, and hit its bottom decreasing values of 2.6 mg/L at 0.5 h after administration. The calculated parameter and fitting curve indicated that the model established in our experiment fitted well.

Conclusions: A PK/PD model illustrates that the relationship between mitiglinide concentration in plasma and glucose lowering effect in healthy volunteers was established. The results of our experiment suggested that the model can be used reasonably to predict the relationship between PK and PD in mitiglinide, which could be used in diabetes mellitus dosage control in clinical trials and other fields.

Keywords: Mitiglinide, Pharmacodynamic, Pharmacokinetic, Pharmacokinetic-pharmacodynamics modeling, Plasma glucose

Background

Type 2 diabetes mellitus, which affects approximately 11% of adults in the U.S. and 8% worldwide [1], is resulted from a progressive decline in insulin action and the reduced response of β-cells to insulin [2, 3]. ATP-sensitive K+ (KATP) channels exists widely in pancreatic cells, cardiac, smooth and skeletal muscles, and central nervous system [4]. Different KATP-channel may exist in different tissues, Kir6.2/SUR1 for β-cells, some neurons cardiac, Kir6.2/SUR2A for skeletal KATP-channels, and Kir6.2/SUR2B for vascular smooth muscle KATP-channels [5].

Mitiglinide is a rapid acting drug for diabetic drugs, which is selectively active on KATP channel of Kir6.2/SUR1 [6, 7]. Previous study has demonstrated that the preprandial administration of mitiglinide was benefit for postprandial hyperglycemia and glycemic control [8]. A series of sensitive HPLC-MS/MS methods have been used to determine the pharmacokinetics (PK) properties of mitiglinide in rats [9] and humans. The PK property of 24 volunteers who received oral administration mitiglinide at a single dose from 5 to 20 mg/kg was studied [10]. The maximum plasma concentration (Cmax) in volunteers with mitiglinide from 5 to 20 mg/kg was 565.30

* Correspondence: 13951672230@163.com
1Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210029, China
Full list of author information is available at the end of the article

© The Author(s). 2017 Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
and 2625.26 ng/mL respectively, and the terminal half-life ($T_{1/2}$) was 1.19 and 1.43 h respectively. Pharmacokinetic–pharmacodynamic population model-based studies may suggest an accurate model to provide information for impact assessment of the treatment [11]. The relationship between the pharmacokinetics of mitiglinide and the drug effects has not been studied in humans. The objective of present study is to measure the relationship between plasma drug concentration and its effects on healthy volunteers with oral administration. The experiment result may be used for prediction the therapeutic active of mitiglinide and its side effect profiles in clinic.

Methods

Drug

Mitiglinide (10 mg/tablet, lot no.14032011, expiration: 29/02/2016) was manufactured by Suzhong Pharma Co. Ltd., Jiangsu, China.

Subjects

The study was approved by the Ethics Committee of the Affiliated Hospital of Nanjing University of Chinese Medicine (IRB#2014NL-020-02). Eighteen healthy male volunteers participated in this study, with average age of 24 (ranging from 18 to 40) and average weight of 67.5 kg (ranging from 56 to 80 kg). All volunteers went through thorough physical examinations and routine laboratory evaluations, including haematology, serum chemistry, virus and urinalysis. None of the volunteers in this study took any drugs which would have affected this study for at least 3 months beforehand. The limitation of our study lies in the fact that subjects were excluded from health problems including drug or alcohol abuse, and the abnormalities in the experiment. All volunteers were informed of the purpose and possible risks before the experiment and the positive ion mode was selected for quantitative analysis. Quantitation was detected by the multi-reaction-monitoring (MRM) mode of transitions of m/z 316.2 → 298.2 for Mitiglinide, m/z 318.2 → 120.2 for Nateglinide. The optimized conditions used for the ESI" source were set as follows: capillary voltage 5.5 KV; turbo heater temperature 600 °C; curtain gas (CUR) 40 psi; collision activation dissociation (CAD) 8 psi; declustering potential (DP) 81 V; collision energy (CE) 23 eV for mitiglinide and 29 eV for IS respectively. Blood glucose concentration was examined by the glucose oxidase method with the use of an autoanalyzer (TosohG8, Japan).

Statistical analysis

Graphical and all other statistical analyses, including the evaluation outputs, were performed within the Phoenix platform [13].

Pharmacokinetic/pharmacodynamic model and data analysis

A two-compartment linked with $E_{\text{max}}$ PK-PD model was implemented by maximizing the log-likelihood using the first-order conditional estimation (FOCE) method of the Phoenix NLME software (Pharsight Corp, St. Louis, Missouri, United States of America). Pharmacokinetics and pharmacodynamics values of mitiglinide were modelled sequentially. The models were established as a series of equations, describing the relationship between plasma medicine and glucose. The equations were solved numerically and fitted to the data with Phoenix NLME [11]. Plasma concentration of mitiglinide was used for the PK analysis. The two-compartment model for oral administration was established by the least-squares method, and the pharmacokinetic parameters including
V, V2, CL and CL2 were also calculated. The amounts of mitiglinide and plasma concentrations in the central compartment (C) were determined and calculated by the distribution volume for the central compartment (V). The two-compartment model as shown in Fig. 1, and the overall PK model could be described as Eqs. (1) to (11) as below:

\[
dA_a/dt = -Ka A_a
\]

(1)

\[
dA_1/dt = Ka A_a - CL C (C - C_2)
\]

(2)

\[
dA_2/dt = CL_2 C (C - C_2)
\]

(3)

\[C = A_1/V\]

(4)

\[C_2 = A_2/V_2\]

(5)

\[Ka = tvKa \exp(\eta Ka)\]

(6)

\[V = tvV \exp(\eta V)\]

(7)

\[V_2 = tvV_2\]

(8)

\[CL = tvCL\]

(9)

\[CL_2 = tvCL_2 \exp(\eta CL_2)\]

(10)

\[T_{lag} = tvT_{lag} \exp(\eta T_{lag})\]

(11)

A means the amount of mitiglinide, A1 and A2 suggest the amounts of drug in the central and peripheral compartments respectively. The concentrations of mitiglinide in the central and peripheral compartment are represented as C and C2 respectively. The elimination clearances of the drug in the central and peripheral compartments are represented as CL and CL2 respectively. TV indicates the typical value of population mean, and \(\eta\) indicates the inter-individual variation. PK parameters were obtained by simultaneously fitting the plasma concentration data after oral administration of mitiglinide (10 mg) to volunteers using the 2-compartment PK model (Table 1).

An Emax PD model was selected based on previous research on describing the relationship between mitiglinide concentrations and the glucose levels in the plasma [14–16]. The Biophase model which consists of compartmental PK model in conjunction with Emax PD model is one of the commonly used PK-PD models. If biophase model could adequately fit both the PK and PD profiles, it would render it possible for further application. The glucose plasma concentration (mg/mL) was the response variables in the experiment, and the model can be described by equations as shown below:

![Fig. 1 Scheme of the pharmacokinetic-pharmacodynamic (PK–PD) model. A1, mitiglinide amounts in the central compartment; A2, mitiglinide amounts in the peripheral compartment; C, mitiglinide concentration in the central compartment; C2, mitiglinide concentration in the peripheral compartment; V, central volume of the distribution of mitiglinide; V2, peripheral compartment; ke0, glucose disappearance rate constant; E, level of glucose in the plasma; E0, blood glucose maintained at a certain level in absence of the drug; Ce, plasma concentration in the effect compartment](image-url)
\[ \frac{dCe}{dt} = Ke0^\ast (C-Ce) \]  \hspace{1cm} (12)

\[ E = E0^\ast (1 - Ce^\ast Gam / (IC50^\ast Gam + Ce^\ast Gam)) \]  \hspace{1cm} (13)

\[ Ke0 = tvKe0^\ast \exp(\eta Ke0) \]  \hspace{1cm} (14)

\[ IC50 = tvIC50 \]  \hspace{1cm} (15)

\[ Gam = tvGam^\ast \exp(\eta Gam) \]  \hspace{1cm} (16)

\[ E0 = tvE0^\ast \exp(\eta E0) \]  \hspace{1cm} (17)

Where \( E \) is the level of glucose in the plasma, \( E_0 \) is the blood glucose maintained at a certain level in absence of the drug. \( C \) is the plasma concentration in the central compartment and \( Ce \) represents the plasma concentration in the effect compartment. \( K_{eo} \) represents the glucose disappearance rate constant. \( TV \) represents the typical value of the population mean and \( \eta \) means the inter-individual variation, and the inter-individual variation for parameters with high shrinkage value (>0.5) were not included in the model.

**Results**

The plasma concentration vs time curve following oral administration of 10 mg of mitiglinide was shown in Fig. 2. Solid line represents the mean concentration of the test coupled with the standard deviation on each time point. Terminal elimination half-life \( (t_{1/2}) \) is 1.69 ± 0.16 h and the CL/F 7.80 ± 1.84 L/h. Figure 2 also shows the glucose profiles after drug administration, the model independent parameters are calculated by using individual approach with Non compartmental analysis, and the model dependent parameters are obtained by using population approach with clearance parameterization. The plasma glucose levels declined after a lag of 0.2 h, and hit its bottom values of 2.6 mg/L by 0.5 h after administration. Mitiglinide declined from 0.2 to 2.2 h after administration. PK parameters were obtained by simultaneously fitting the plasma concentration data after oral administration of mitiglinide to volunteers using the 2-compartment model.

The two-compartment model analyzes the results based on the maximum likelihood criterion and visual inspection of the fittings. The data was calculated by the first-order absorption with a lag time and linear elimination. Non-compartmental and population modeling parameters are listed in Tables 1 and 2. PK/PD was analyzed based on the pharmacokinetic parameters obtained from the test as an input function. Figure 3 illustrates the fitting result of the plasma concentration and plasma glucose levels with population PK-PD model where the solid line represents the best fit of the model.

The diagnosis chart of final model was shown in Fig. 4. A is the scatter plots which represents the conditional weighted residuals (CWRES) and independent variable (IVAR). The CWRES distribution of the final model is narrow, and uniform on both sides of the zero line, which indicates that the model fitted well. B is the final model CWRES on the PRED of the scatter diagram. The value of CWRES ranged between 2 and −2 indicating the minor differences in prediction model. C is the observed value (DV) of individual predicted value (IPRE)

![Fig. 2](image-url) Plasma mitiglinide concentration and plasma glucose concentration after a single oral dose of 10 mg mitiglinide to healthy volunteers (mean ± SD, n = 18)

| Parameter | Mean ± SD |
|-----------|-----------|
| \( t_{1/2} \) (h) | 1.69 ± 0.16 |
| \( T_{\text{max}} \) (h) | 0.25 (0.17–0.50) |
| CL/F (L/h) | 7.80 ± 1.84 |
| Vd/F (L) | 23.96 ± 7.23 |
| \( C_{\text{max}} \) (ng/mL) | 1165.10 ± 357.50 |
| AUC \(_{0-1}\) (ng/mL·h) | 1499.20 ± 339.73 |
| AUC\(_{0-\infty}\) (ng/mL·h) | 1489.60 ± 336.85 |
| AUC\(_{0-\infty}\) / AUC\(_{0-1}\) (%) | 99.51 ± 0.16 |
scatter diagram and D is the observed concentrations (DV) versus population predicted values (PRED).

Based the results above, the two-compartment PK model of first-order absorption with a lag time and linear elimination conjunction with biophase PD model was developed which could capture both PK and PD profiles of mitiglinide in the present reasonably well.

**Discussion**

**Pharmacokinetics**

Mitiglinide could reduce the early-phase insulin release and promote the controlling of the postprandial glucose levels with its ability to fasten insulin secretagogue [17]. The characteristic of mitiglinide of anti-hyperglycemic can take effect more rapidly compared with sulphonylureas. The fast release of insulin within a few minutes was due to the rapid absorption rate of mitiglinide after oral administration [18]. In the 90% confidence internal of geometric mean ratios, mitiglinide reached its peak plasma concentration (C_max) and AUC_last, which represented the area under the plasma concentration-time curve from time zero to the time of the last measurable concentration, were observed as 0.9694 (0.8120, 1.1573) and 0.8951 (0.8440, 0.9494), respectively [19]. Mitiglinide could bind to the SUR and activate it in the pancreatic β-cells, which was considered as the mechanism of the drug underlying the therapeutic effect [20, 21]. In the present study, mitiglinide was given by oral administration and the short elimination half-life, t_{1/2} (h) was 1.69. Therefore, the fast absorption in the first 2 h may be caused by the binding of the free form drug to the SUR. The total clearance (CL/F) was 7.79 mL/h in our study, which is comparable to rat (0.83 mL/h) in previous studies [22].

**PK-PD modeling of glucose lowering effects**

The characters of PK behaviors and its influences to the values of plasma glucose levels have been studied in several hypoglycemic drugs [23, 24]. Toshiyuki Takanohashi et al. reported the pk-pd. modeling methodology to describe the rapidity therapeutic effect of mitiglinide by using the receptor-binding-dissociation in rats [12]. However, model of inhaled glucose in healthy humans has not been published previously. Phoenix platform is the commonly used software to investigate PK/PD characters depending on the 2-compartment model [25, 26]. Our study analyzed the effects of mitiglinide on glucose lowering after a single oral dose. The shorter duration action of mitiglinide and the decreasing glucose levels in

| Table 2 | Population modeling parameters for mitiglinide after a single 10 mg oral dose to healthy volunteers (mean ± SD, n = 18) |
|-----------------|-------------------|-----------------|
| **Parameter**   | **Mean ± SD**     | **Inter-individual variability (CV %)** |
| Ka (/h)         | 9.57 ± 2.38       | 91.95           |
| Tlag (h)        | 0.09 ± 0.01       | 70.71           |
| V (L)           | 6.15 ± 0.33       | 17.61           |
| CL (L/h)        | 0.03 ± 0.01       | -               |
| V2 (L)          | 104.69 ± 11.37    | -               |
| CI2 (L/h)       | 9.85 ± 0.51       | 22.18           |
| IC50 (μg/mL)    | 1.13 ± 0.08       | -               |
| E0 (mmol/L)     | 4.65 ± 0.09       | 4.35            |
| Ke0 (/h)        | 7.47 ± 1.89       | 90.61           |
| Gamma           | 1.66 ± 0.18       | 18.67           |

![Fig. 3](Image) Population fitting of plasma mitiglinide concentration and plasma glucose concentration after a single oral dose of 10 mg mitiglinide to healthy volunteers (Left: Population prediction of plasma concentration vs time, Right: Population Prediction of glucose concentration vs time). The solid line is the best fit of the PK-PD model. (DV, Dependent value; PRED, Population prediction)
plasma was described by a two-compartment model followed by the least-squares method. The fitting results were adequate, and the efficacy of the drug has been appropriated proposed by the empirical biexponential equation. Furthermore, the model is flexible for the concentration and efficiency of the

Fig. 4 Diagnostic plots of the final Population PK-PD model for mitiglinide from studies. Diagnostic plots include (a) Conditional weighted residuals (CWRES) and independent variable (IVAR), (b) weighted residuals versus predicted values (PRED), (c) Plot of the observed value (DV) versus individual population predicted values (IPRE) and (d) The observed value versus population predicted values (PRED)
drug. The $T_{\text{max}}$ (h) of mitiglinide was 0.25 (0.17–0.50) in our study and the glucose decrease reached its maximum.

Although mitiglinide is a commonly used and effective drug for diabetes mellitus in clinic, its side effects and the interaction remain to be studied further. A recent investigation shows that mitiglinide treatment could significantly decrease plasma fibroblast growth factor levels, which would have various effects on pancreatic islets [27]. Our results may illustrate the physiological effects of mitiglinide and its relationship with plasma concentration. Different kinds of indirect response models can be used to explain the pk-pd. property of drug. In our study, we investigated glucose disappearance and mitiglinide concentration levels in plasma by building the pk-pd. modeling. The CWRES distribution of the final model uniformed on both sides of the zero line, and the value ranged between 2 and –2 indicating the minor differences in prediction model. The result of our research could describe the drug’s pharmacological action. The results of our experiment are benefit for study designs and appropriate dosage selection of diabetes mellitus in clinical trials.

Conclusions
A PK/PD model illustrates that the relationship between mitiglinide concentration in plasma and glucose lowering effect in healthy Chinese volunteers was established. The PK data of mitiglinide after oral administration were analyzed by a two-compartment model of first-order absorption with a lag time and linear elimination. The results of our experiment suggested that the model can be used reasonably to predict the relationship between PK and PD in mitiglinide. The established PK-PD model may be used to describe the drug’s pharmacological action. The results of our experiment are flexible for the concentration and efficiency of the drug and may be used for study designs and diabetes mellitus dosage control in clinical trials.

Availability of data and materials
All the data and material of the project are in availability and saved at Affiliated Hospital of Nanjing University of Chinese Medicine.

Funding
The authors are grateful for the financial support provided by the National Natural Science Foundation of China (No. 81403174 and 81503300), the Natural Science Foundation of Jiangsu province (No. BK20131035, BK20151602, and BK20151602), Jiangsu Provincial Medical Youth Talent (No. QNRC2016642) and the top six talent project of Jiangsu province 2016 (WSN-051).

Authors’ contributions
SL contributed to the main conception and design of the study, collection, analysis and interpretation of the data, performed statistical analysis and drafted the manuscript. PC contributed to the main conception and design of the study, collection, analysis and interpretation of the data. BS performed some of the laboratory tests. YW performed some of the laboratory tests. AD revised the manuscript critically and gave final approval of the version to be published. WJ contributed to the main conception and design of the study, collection, analysis and interpretation of the data and gave final approval of the version to be published. All authors read and approved the final manuscript.

Ethics approval and consent to participate
The study was approved by the Ethics Committee of the Affiliated Hospital of Nanjing University of Chinese Medicine (IRB#2014NL-020-02). All subjects were informed in oral and written form that they could withdraw from the trial any time for any reason. Consent was obtained in written form before any trial-related activities, and the investigator retained the consent forms.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1 Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210029, China. 2 Nanjing University of Chinese Medicine, Nanjing, Jiangsu 210016, China. 3 Office of Pharmaceutical Quality, Center of Drug Evaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, MD 20903, USA.

Received: 22 December 2016 Accepted: 26 June 2017
Published online: 04 July 2017

References
1. Franz MJ, Boucher JL, Rutten-Ramos S, VanWormer JJ. Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. J Acad Nutr Diet. 2015;115:1447–63.
2. Tahara A, Matsuyama-Yokono A, Shibasaki M. Effects of antidiabetic drugs in high-fat diet and streptozotocin–nicotinamide-induced type 2 diabetic mice. Eur J Pharmocol. 2011;655:108–16.
3. Guerrero-Berros E, Schmeder J, Bein MS. Neuropathology of type 2 diabetes: a short review on insulin-related mechanisms. Eur Neuropsychopharmacol. 2014;24:1961–6.
4. Ashcroft FM, Gribble FM. ATP-sensitive K+ channels in health and disease. Diabetologia. 1999;42:903–19.
5. Lim JG, Lee HY, Yun JE, Kim SP, Park JW, Suh SJ, Jang BC, Cho CH, Bae JH, Kim SS, Han J, Park MJ, Song DK. Taurine block of cloned ATP-sensitive Kt channels with different sulfonylurea receptor subunits expressed in Xenopus laevis oocytes. Biochem Pharmacol. 2004;68:901–10.
6. Ohnita H, Koizumi T, Tsutsui M, Kobayashi M, Inoue S, Sato F. Novel rapidand short-acting hypoglycemic agent, a calcium (2s)-2-benzyl-3-(cishexahydro-2-isoinolinolycarbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide. J Pharmacol Exp Ther. 1994;269:889–95.
7. Sunaga Y, Gono T, Shibasaki T, Chikawa K, Kusama H, Yano H, Seino S. The effects of mitiglinide (KAD-1229), a new anti-diabetic drug, on ATP-sensitive Kt channels and insulin secretion: comparison with the sulfonylureas and nateglinide. Eur J Pharmacol. 2001;431:119–25.
8. Assaloni R, Da Ros R, Quagliaro L, Picioni L, Maier A, Zuodar G, Motz E, Cerello A. Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients. Diabetologia. 2005;48:1919–24.
9. Lushan Y, Su Z. Determination of mitiglinide in rat plasma by high-performance liquid chromatography with UV detection. J Chromatogr B AnalytTechnol Biomed Life Sci. 2006;834:204–7.
10. Zhang J, Cai LJ, Peng WX, Zhu RH, Yang J, Zhang QZ. The effects of food on the pharmacokinetics of mitiglinide tablets in healthy volunteers and a novel mass-spectrometric (UPLC-MS/MS) method for such studies. J Clin Pharm Ther. 2012;37:95–9.
11. Lemenuel-Diot A, Lavelle C, Frey N, Jochemsen R, Mallet A. Mixture modeling for the detection of subpopulations in a pharmacokinetic pharmacodynamic analysis. J Pharmacokinet Pharmacodyn. 2007;34:157–81.
12. Takano T, Ariake K, Uebukata K, Hayashi M, Yamada Y. Comparison of the rapidity of onset of the therapeutic effect between mitiglinide by PK/PD analysis in rats. Eur J Drug Metab Pharmacokinet. 2012;37:9–15.

13. Vu T, Ma P, Xiao J, Wang YM, Malik F, Chow AT. Population Pharmacokinetic-Pharmacodynamic Modeling of Omecamtiv Mecarbil, a Cardiac Myosin Activator, in Healthy Volunteers and Patients With Stable Heart Failure. J Clin Pharmacol. 2015;55:1236–47.

14. Yun HY, Park H, Kang W, Kwon K. Pharmacokinetic and pharmacodynamic modeling of the effects of mitglinide on insulin secretion and glucose lowering in healthy humans. J Clin Pharm Ther. 2006;31:469–76.

15. Reddy MB, Yang KH, Yang TH, Chow AT. Population pharmacokinetic-pharmacodynamic modeling of mitglinide in healthy volunteers and patients with type 2 diabetes mellitus. J Clin Pharmacol. 2015;55:1236–47.

16. Liu D, Lon HK, Dubois DC, Almon RR, Josko WJ. Population pharmacokinetic-pharmacodynamic–disease progression model for effects of anakinra in Lewis rats with collagen-induced arthritis. J Pharmacokin Pharmacodyn. 2011;38:769–86.

17. Guanardo-Mendoza R, Priddle A, Jimenez-Ceja LM, Socas A, Foll F. The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of Type 2 diabetes mellitus. Arch Med Sci. 2013;9:336–43.

18. Domoritz A. Insulinootropic meglitinide analogues. Lancet. 2001;358:1709–16.

19. Jung KA, Kim JH, Kim SR, Kim HJ, Lee SY, Ko JW, Huh W. Pharmacokinetics of a fixed-dose combination of mitglinide and metformin versus concurrent administration of individual formulations in healthy subjects: a randomized, open-label, two-treatment, two-period, two-sequence, single-dose, crossover study. Clin Drug Investig. 2012;32:799–804.

20. Maruyama I, Tomiyama Y, Maruyama K, Ojima K, Kobayashi K, Kobayashi M, Yamazaki Y, Kobima M, Shibata N. Effects of mitglinide and sulfonylureas in isolated canine coronary arteries and perfused rat hearts. J Pharmacol. 2001;531:194–200.

21. Blickle JF. Meglitinide analogues: a review of clinical data focused on recent trials. Diabetes Metab. 2006;32:113–20.

22. Zeng Y, Xie X, Duan J, Zhou T, Zhang Y, Yang M, Xu F. Perturbation of mitglinide metabolism by chronic unpredicted mild stress in rats. Sci Rep. 2014;4:3794.

23. Li H, Xu J, Fan X. Target-mediated pharmacokinetic/pharmacodynamic model based meta-analysis and dosing regimen optimization of a long-acting release formulation of exenatide in patients with type 2 diabetes mellitus. J Pharmacol Sci. 2015;127:170–80.

24. Landersdorfer CB, Josko WJ. Pharmacokinetic pharmacodynamics modeling of glucose clamp effects of inhaled and subcutaneous insulin in healthy volunteers and diabetic patients. Drug Metab Pharmacokinet. 2010;25:418–29.

25. Kobuchi S, Ito Y, Hayakawa T, Nishimura A, Shibata N, Takada K, Sakaeda T. Pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for erythropenia in rats. J Pharmacol Toxicol Methods. 2014;70:134–44.

26. Wang J, Xia S, Xue W, Wang D, Sai Y, Liu L, Liu X. A semi physiologically based pharmacokinetic model characterizing mechanism-based auto-inhibition to predict stereoselective pharmacokinetics of verapamil and its metabolite norverapamil in human. Eur J Pharm Sci. 2013;50:290–302.

27. Wang B, Yang G, Yang M, Liao Y, Li Z, Boden G, Li L. Mitiglinide treatment may decreases plasma fibroblast growth factor-21 levels in individuals with new-onset T2DM. Cytokine. 2012;57:300–3.